€2.55M granted to SubAlgic, a collaborative R&D consortium headed by Theralpha, which includes Synprosis, the Institute of Molecular and Cellular Pharmacology and the Center of Clinical Investigation, for the development of Theralpha drug candidate THA903
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and the fortnightly R&D Express, tracking reforms and investments in central and eastern Europe.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.